Figure 3: Distribution of β-CTx in the study groups. In patients with BMD (no tumor) 75.45% were of normal activity, 24.55% were pathological elevated. Patients with tumor but without bone metastases showed normal activity in 13.33% and elevated levels of β-CTx in 86.67%. The β-CTx levels were normal in 0.0% of all patients with known bone metastases and elevated in 100.0%